The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer
Authors
Keywords
Ovarian Cancer, Erlotinib, Epithelial Ovarian Cancer, Ovarian Cancer Cell, Fallopian Tube
Journal
Molecular Diagnosis & Therapy
Volume 20, Issue 3, Pages 199-212
Publisher
Springer Nature
Online
2016-04-30
DOI
10.1007/s40291-016-0201-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Hepatocyte growth factor secreted by ovarian cancer cells stimulates peritoneal implantation via the mesothelial–mesenchymal transition of the peritoneum
- (2015) Michihiko Nakamura et al. GYNECOLOGIC ONCOLOGY
- Expression and Significance of CD44, CD47 and c-met in Ovarian Clear Cell Carcinoma
- (2015) Huimin Wang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Patient-centric trials for therapeutic development in precision oncology
- (2015) Andrew V. Biankin et al. NATURE
- A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors
- (2015) David S. Hong et al. Oncotarget
- INC280, an orally available small molecule inhibitor of c-MET, reduces migration and adhesion in ovarian cancer cell models
- (2015) Kim Moran-Jones et al. Scientific Reports
- A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene
- (2015) Yuji Tada et al. SpringerPlus
- A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors
- (2014) S. Pant et al. ANNALS OF ONCOLOGY
- Dualistic Classification of Epithelial Ovarian Cancer: Surgical and Survival Outcomes in a Large Retrospective Series
- (2014) Pierluigi Benedetti Panici et al. ANNALS OF SURGICAL ONCOLOGY
- Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma
- (2014) A Patnaik et al. BRITISH JOURNAL OF CANCER
- HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma
- (2014) Y J Liu et al. BRITISH JOURNAL OF CANCER
- Microenvironment-Derived HGF Overcomes Genetically Determined Sensitivity to Anti-MET Drugs
- (2014) S. Pennacchietti et al. CANCER RESEARCH
- Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib Onartuzumab in Advanced Non-Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit
- (2014) H. Koeppen et al. CLINICAL CANCER RESEARCH
- Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic
- (2014) D. L. F. Jardim et al. CLINICAL CANCER RESEARCH
- Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies
- (2014) R. Salgia et al. CLINICAL CANCER RESEARCH
- Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma
- (2014) Akiko Kawano Nagatsuma et al. Gastric Cancer
- Immunohistochemical application of a highly sensitive and specific murine monoclonal antibody recognising the extracellular domain of the human hepatocyte growth factor receptor (MET)
- (2014) Aaron M Gruver et al. HISTOPATHOLOGY
- Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cellsviacMet pathway through HGF-dependent and -independent mechanisms
- (2014) Isabelle Matte et al. INTERNATIONAL JOURNAL OF CANCER
- Extended Progression-Free Survival in Two Patients With Alveolar Soft Part Sarcoma Exposed to Tivantinib
- (2014) John M. Goldberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
- (2014) Timothy Iveson et al. LANCET ONCOLOGY
- The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance
- (2014) Christiane R. Maroun et al. PHARMACOLOGY & THERAPEUTICS
- The target therapy of ovarian clear cell carcinoma
- (2014) Ying Jin et al. OncoTargets and Therapy
- Origin and molecular pathogenesis of ovarian high-grade serous carcinoma
- (2013) R. J. Kurman ANNALS OF ONCOLOGY
- Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET
- (2013) C. Basilico et al. CLINICAL CANCER RESEARCH
- A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study
- (2013) Lainie P. Martin et al. GYNECOLOGIC ONCOLOGY
- Ligand-independent activation of MET through IGF-1/IGF-1R signaling
- (2013) Andreas Varkaris et al. INTERNATIONAL JOURNAL OF CANCER
- A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer
- (2013) Yoon-Koo Kang et al. INVESTIGATIONAL NEW DRUGS
- Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2013) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Developing biomarkers to predict benefit from HGF/MET pathway inhibitors
- (2013) Hartmut Koeppen et al. JOURNAL OF PATHOLOGY
- Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement
- (2013) Richard Schwab et al. LUNG CANCER
- MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas
- (2013) Sang Y Ha et al. MODERN PATHOLOGY
- HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors
- (2013) E. Penuel et al. MOLECULAR CANCER THERAPEUTICS
- Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment
- (2013) Y Kwon et al. ONCOGENE
- Prognostic Value and Clinical Pathology of MACC-1 and c-MET Expression in Gastric Carcinoma
- (2013) Jie Ma et al. PATHOLOGY & ONCOLOGY RESEARCH
- Met Is the Most Frequently Amplified Gene in Endometriosis-Associated Ovarian Clear Cell Adenocarcinoma and Correlates with Worsened Prognosis
- (2013) Yoriko Yamashita et al. PLoS One
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation
- (2013) Guy Betts et al. VIRCHOWS ARCHIV
- New insights into ovarian cancer pathology
- (2012) J. Prat ANNALS OF ONCOLOGY
- MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome
- (2012) H E Lee et al. BRITISH JOURNAL OF CANCER
- Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib
- (2012) Jonathan W. Goldman et al. CANCER
- Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
- (2012) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Assessment of Hepatocyte Growth Factor in Ovarian Cancer Mortality
- (2011) E. L. Goode et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- MET Expression and Amplification in Patients with Localized Gastric Cancer
- (2011) Y. Y. Janjigian et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors
- (2011) L. S. Rosen et al. CLINICAL CANCER RESEARCH
- IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer
- (2011) M. S. Anglesio et al. CLINICAL CANCER RESEARCH
- Increased circulating hepatocyte growth factor (HGF): A marker of epithelial ovarian cancer and an indicator of poor prognosis
- (2011) Guro Aune et al. GYNECOLOGIC ONCOLOGY
- Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm
- (2011) Robert J. Kurman et al. HUMAN PATHOLOGY
- Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- METAmplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
- (2011) Jochen K. Lennerz et al. JOURNAL OF CLINICAL ONCOLOGY
- c-Met activation through a novel pathway involving osteopontin mediates oncogenesis by the transcription factor LSF
- (2011) Byoung Kwon Yoo et al. JOURNAL OF HEPATOLOGY
- Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient
- (2011) Sohei Yamamoto et al. MODERN PATHOLOGY
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma
- (2011) Q. Xie et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ovarian Cancer Development and Metastasis
- (2010) Ernst Lengyel AMERICAN JOURNAL OF PATHOLOGY
- A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2
- (2010) J. P. Eder et al. CLINICAL CANCER RESEARCH
- Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor-Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors
- (2010) M. S. Gordon et al. CLINICAL CANCER RESEARCH
- The effect of hepatocyte growth factor on the initial stages of mouse follicle development
- (2010) M.C. Guglielmo et al. JOURNAL OF CELLULAR PHYSIOLOGY
- HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma
- (2010) Rong Bu et al. LABORATORY INVESTIGATION
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
- (2010) Ignace Vergote et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
- (2008) R. W. Tothill et al. CLINICAL CANCER RESEARCH
- Expression and mutational analysis ofMETin human solid cancers
- (2008) Patrick C. Ma et al. GENES CHROMOSOMES & CANCER
- EGF and HGF levels are increased during active HBV infection and enhance survival signaling through extracellular matrix interactions in primary human hepatocytes
- (2008) Ana Paula Barreiros et al. INTERNATIONAL JOURNAL OF CANCER
- Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion
- (2007) E.C. KOON et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started